Objective
to report the 3-year clinical outcomes of P2Y12 inhibitor monotherapy following 3 months DAPT as compared to DAPT for 12 months or longer after PCI
Study
multicentre, prospective, randomised trial (non-inferiority)
Population
patients undergoing PCI with drug-eluting stents
Endpoints
major adverse cardiac and cerebrovascular events at 3 years (all-cause death, MI or stroke)
Conclusion
P2Y12 inhibitor monotherapy after 3 months DAPT was associatedwith similar 3-year major adverse event rates as compared to prolonged DAPT in patients undergoing PCI
Choi et al. JAMA Cardiol. 2022; 7:1100-08